What factors drove the changes in NeuroOne Medical's revenue and profit?

What guidance did NeuroOne Medical's management provide for the next earnings period?

What were the key takeaways from NeuroOne Medical's earnings call?

What were the key takeaways from NeuroOne Medical’s earnings call?

Did NeuroOne Medical beat or miss consensus estimates last quarter?

What does NeuroOne Medical do and what are its main business segments?

What is NeuroOne Medical's gross profit margin?

What is the revenue and EPS growth rate for NeuroOne Medical year over year?

- **Revenue Surge**: Q3 product revenue up 105% to $1.7 million, with full-year guidance of $8-10 million (132%-190% YoY growth).
- **Margin Expansion**: Gross margin improved to 53.9%, with updated FY2025 target of 50-53%.
- **Patient Success**: First patient achieved 1-year seizure freedom, highlighting OneRF's clinical impact.
- **New Markets**: FDA 510(k) submitted for trigeminal neuralgia, and SCS electrode design targeting $3B lower back pain market.
- **Financial Strength**: Debt-free with $8 million cash, $8.2 million raised in April, and 46% net loss improvement.

**【CEO Summary Section】**
- **Revenue Growth**: Product revenue surged 105% to $1.7 million in Q3 FY2025, with gross margins improving to 53.9% (vs. 34.1% in Q3 FY2024). Full-year guidance updated to $8-10 million revenue (132%-190% YoY growth) and 50-53% gross margins.
- **Patient Outcomes**: Celebrated first patient achieving 1-year seizure freedom using OneRF ablation system, with plans for a post-market registry to track outcomes.
- **New Market Expansion**: 
  - Submitted FDA 510(k) for trigeminal neuralgia ablation, targeting 150,000 U.S. patients.
  - Developing basivertebral nerve ablation for lower back pain, with $3B annual market potential.
  - Received first order for drug delivery system from biotech partner, combining therapy and diagnostics.
- **Strategic Strengths**: Debt-free with $8 million cash, $8.2 million raised in April, and ISO 13485 certification underway for international expansion.
- **IP & Talent**: Secured first international patent for spinal cord stimulation electrode and hired Chief Medical Adviser Dr. Parag Patil.

**【CFO Financial Commentary】**
- **Q3 Financials**: 
  - Product revenue: $1.7 million (105% YoY growth).
  - Gross profit: $0.9 million (53.9% of revenue).
  - Operating expenses: $2.8 million (9% YoY decline).
  - Net loss: $1.5 million (46% improvement vs. Q3 FY2024).
- **Cash Position**: $8 million as of June 30, 2025 (vs. $1.5 million in Q3 FY2024), with $8.2 million raised in April.
- **Licensing Revenue**: $3 million in first 9 months of FY2025 from Zimmer Biomet agreement.

**【Q&A Key Highlights】**
- **Drug Delivery System**: In animal testing phase, with potential for human trials if successful.
- **Trigeminal Ablation**: Targeting neurosurgeons who already use OneRF for brain ablation, with 150,000 U.S. patients.
- **Spinal Cord Stimulation (SCS)**: Electrode design covers broader spine area, with multiple SKUs planned for different pain levels.
- **2026 Outlook**: No guidance yet, but funded through FY2026 with potential extension if milestones met.

NeuroOne Medical Technologies Corporation (NMTC) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

NMTC

NMTC fundamentals

You can ask Aime